Cargando…

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

BACKGROUND: Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Guancial, Elizabeth A., Kilari, Deepak, Xiao, Guang-Qian, Abu-Farsakh, Sohaib H., Baran, Andrea, Messing, Edward M., Kim, Eric S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871463/
https://www.ncbi.nlm.nih.gov/pubmed/27187160
http://dx.doi.org/10.1371/journal.pone.0155503
_version_ 1782432597271379968
author Guancial, Elizabeth A.
Kilari, Deepak
Xiao, Guang-Qian
Abu-Farsakh, Sohaib H.
Baran, Andrea
Messing, Edward M.
Kim, Eric S.
author_facet Guancial, Elizabeth A.
Kilari, Deepak
Xiao, Guang-Qian
Abu-Farsakh, Sohaib H.
Baran, Andrea
Messing, Edward M.
Kim, Eric S.
author_sort Guancial, Elizabeth A.
collection PubMed
description BACKGROUND: Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC. METHODS: A cohort of 19 clinically annotated, archived, fresh frozen RC specimens from patients with MIBC treated with Pt-based NAC was identified [ypT0 (pathologic complete response, pCR), N = 4; ≤ypT1N0M0 (pathologic partial response, pPR), N = 6; ≥ypT2 (minimal pathologic response/progression), N = 9)]. RC specimens from 2 patients with MIBC who did not receive NAC and 1 treated with a non-Pt containing NAC regimen were used as negative controls. Total Pt concentration in normal adjacent urothelial tissue and bladder tumors from RC specimens was measured by flameless atomic absorption spectrophotometry. RESULTS: Total Pt concentration in normal urothelium differed by tumor pathologic response (P = 0.011). Specimens with pCR had the highest Pt concentrations compared to those with pPR (P = 0.0095) or no response/progression (P = 0.020). There was no significant difference in Pt levels in normal urothelium and tumor between pPR and no response/progression groups (P = 0.37; P = 0.25, respectively). Conclusions: Our finding of increased intracellular Pt in RC specimens with pCR following NAC for MIBC compared to those with residual disease suggests that enhanced Pt accumulation may be an important determinant of Pt sensitivity. Factors that modulate intracellular Pt concentration, such as expression of Pt transporters, warrant further investigation as predictive biomarkers of response to Pt-based NAC in MIBC.
format Online
Article
Text
id pubmed-4871463
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48714632016-05-31 Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Guancial, Elizabeth A. Kilari, Deepak Xiao, Guang-Qian Abu-Farsakh, Sohaib H. Baran, Andrea Messing, Edward M. Kim, Eric S. PLoS One Research Article BACKGROUND: Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC. METHODS: A cohort of 19 clinically annotated, archived, fresh frozen RC specimens from patients with MIBC treated with Pt-based NAC was identified [ypT0 (pathologic complete response, pCR), N = 4; ≤ypT1N0M0 (pathologic partial response, pPR), N = 6; ≥ypT2 (minimal pathologic response/progression), N = 9)]. RC specimens from 2 patients with MIBC who did not receive NAC and 1 treated with a non-Pt containing NAC regimen were used as negative controls. Total Pt concentration in normal adjacent urothelial tissue and bladder tumors from RC specimens was measured by flameless atomic absorption spectrophotometry. RESULTS: Total Pt concentration in normal urothelium differed by tumor pathologic response (P = 0.011). Specimens with pCR had the highest Pt concentrations compared to those with pPR (P = 0.0095) or no response/progression (P = 0.020). There was no significant difference in Pt levels in normal urothelium and tumor between pPR and no response/progression groups (P = 0.37; P = 0.25, respectively). Conclusions: Our finding of increased intracellular Pt in RC specimens with pCR following NAC for MIBC compared to those with residual disease suggests that enhanced Pt accumulation may be an important determinant of Pt sensitivity. Factors that modulate intracellular Pt concentration, such as expression of Pt transporters, warrant further investigation as predictive biomarkers of response to Pt-based NAC in MIBC. Public Library of Science 2016-05-17 /pmc/articles/PMC4871463/ /pubmed/27187160 http://dx.doi.org/10.1371/journal.pone.0155503 Text en © 2016 Guancial et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Guancial, Elizabeth A.
Kilari, Deepak
Xiao, Guang-Qian
Abu-Farsakh, Sohaib H.
Baran, Andrea
Messing, Edward M.
Kim, Eric S.
Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title_full Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title_fullStr Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title_full_unstemmed Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title_short Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
title_sort platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871463/
https://www.ncbi.nlm.nih.gov/pubmed/27187160
http://dx.doi.org/10.1371/journal.pone.0155503
work_keys_str_mv AT guancialelizabetha platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT kilarideepak platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT xiaoguangqian platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT abufarsakhsohaibh platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT baranandrea platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT messingedwardm platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer
AT kimerics platinumconcentrationandpathologicresponsetocisplatinbasedneoadjuvantchemotherapyinmuscleinvasivebladdercancer